Home
News
Université Libre de Bruxelles · Faculty of Pharmacy

Where chemistry meets medicine.

The Laboratory of Medicinal and Translational Chemistry designs and synthesizes novel small molecules to combat human disease — with a focus on smart drugs for cancer immunotherapy.

Scroll to explore
44+
Publications
8
Team Members
15+
Years of Research
3
Active Research Areas

Multi-disciplinary science at the frontier of medicine

At the LMTC, we are dedicated to advancing medicinal chemistry and translational science. Our research leverages complementary, multi-disciplinary skills to advance both fundamental projects and practical applications — from drug discovery to novel anticancer medicines.

Our work is rooted in synthetic and bioorganic chemistry, as well as inorganic medicinal chemistry — branching into nanomedicine, theoretical chemistry, oncology, and biomedical sciences.

01 ·
Cancer Immunotherapy
Design and synthesis of small molecules targeting the innate immune pathway. Pioneering STING agonists for glioblastoma and other solid tumors.
02 ·
Inorganic Medicinal Chemistry
Novel metal-based anticancer therapeutics: platinum, gold, ruthenium and osmium complexes with targeted activity and improved selectivity profiles.
03 ·
Drug Design & Synthesis
Exploration of halogen bonding, molecular self-assembly, theoretical chemistry and rational drug design to identify new therapeutic leads.

"When it comes to atoms, language can be used only as in poetry. The poet, too, is not nearly so concerned with describing facts as with creating images."

— Niels Bohr

Prof. Gilles
Berger

Biography Career Research Awards Grants Teaching Publications ↗ Talks & Conferences
Associate Professor · PharmD-PhD
Université Libre de Bruxelles · Faculty of Pharmacy

Prof. Gilles Berger is a translational medicinal chemist with a uniquely broad profile spanning the full spectrum of drug discovery — from computational design and chemical synthesis to in vitro biology and in vivo preclinical models. He leads the Laboratory of Medicinal and Translational Chemistry (LMTC) at the Université Libre de Bruxelles (ULB), where he was appointed Associate Professor in 2021.

After graduating as a Pharmacist (PharmD, magna cum laude, 2005), he gained early industry experience at Pfizer and Erfa before pursuing a PhD in pharmaceutical sciences at ULB (2013), focusing on asymmetric synthesis and anticancer platinum complexes. His postdoctoral journey took him to some of the world's most prestigious research environments: the Hanessian Lab at Université de Montréal, the Lippard Lab at MIT (Fulbright & BAEF Fellow), and Harvard Medical School, where he worked on glioblastoma immunotherapy and the STING innate immunity pathway — then spent six months as Visiting Scholar at the Wyss Institute at Harvard.

His current research focuses on the design and synthesis of precision prodrugs and immunomodulatory agents for cancer therapy and chronic inflammatory diseases, with a particular emphasis on the cGAS-STING pathway. With 45 publications and growing — including papers in PNAS, JACS, Angew. Chemie, and Trends in Molecular Medicine — his work bridges fundamental chemistry and translational medicine with real clinical impact.

45
Publications
21
First-author papers
10+
Awards & Fellowships
2.5M+
€ in funding

Career Timeline

2021 — Present · Brussels, Belgium
Associate Professor & PI — Université Libre de Bruxelles
Head of the Laboratory of Medicinal and Translational Chemistry (LMTC). Leading research in precision prodrug design, cancer immunotherapy, and innate immunity modulation. Building a team of PhD students, postdocs, and master students. Teaching Medicinal Chemistry, Pharmacology and Drug Design at ULB and UMONS.
2021 · Cambridge, USA
Visiting Scholar — Wyss Institute at Harvard
David Mooney Lab. Advancing intracranial immunotherapies for brain cancers combining biodegradable implants with innate immunity activators and checkpoint inhibitors.
2019 — 2020 · Boston, USA
Research Fellow — Harvard Medical School
Sean Lawler Lab, Brigham and Women's Hospital. Pioneered research on STING pathway activation in glioblastoma immunotherapy. Led a landmark PNAS study demonstrating NK-cell mediated tumor regression through STING activation. Awarded the Andrew Parsa Young Investigator Award (SNO 2021).
2017 — 2019 · Brussels, Belgium
Postdoctoral Associate — Université Libre de Bruxelles
RD3 — Microbiology, Bioorganic and Macromolecular Chemistry. Drug design and synthesis. Anticancer metallodrugs. Halogen bonding and supramolecular recognition. FNRS Postdoctoral Fellow.
2015 — 2017 · Cambridge, USA
Postdoctoral Fellow — MIT
Stephen J. Lippard Lab. Development of novel anticancer metallodrugs targeting cisplatin-resistant cancer stem cells. Nanodelivery of anticancer agents using tobacco mosaic virus and squalenoyl nanoparticles. Funded by a Fulbright Scholarship and the Belgian American Educational Foundation (BAEF).
2014 · Montreal, Canada
Postdoctoral Associate — Université de Montréal
Stephen Hanessian Lab. Organic synthesis, bioorganic chemistry, folding properties of modified prolines. Organocatalysis and total synthesis. Published in Angew. Chemie (first author) and Eur. J. Org. Chem.
2008 — 2013 · Brussels, Belgium
PhD — Université Libre de Bruxelles
Doctoral thesis: "Synthesis of chiral vicinal diamines and in vitro anticancer properties of their platinum(II) coordinates." Advisors: Prof. François Dufrasne and Prof. Jean Nève. Combined organic synthesis, theoretical chemistry (DFT), and anticancer biology.
2005 — 2008 · Industry
Pharmacist — Pfizer & Erfa
Industry experience as a licensed pharmacist prior to entering academic research. Provides a grounded perspective on the pharmaceutical development pipeline and translational research.

Research Directions

The LMTC's research orbits around a central ambition: designing smart drugs that act precisely where and when they are needed. Our work integrates synthetic chemistry, computational modeling, and translational biology to bring novel therapeutic concepts to life.

01 ·
cGAS-STING Immunotherapy
The STING pathway sits at the crossroads of innate immunity and cancer biology. We design and evaluate small molecules that modulate this pathway — activating it to heat up cold tumors, or inhibiting it to suppress chronic sterile inflammation in age-related diseases.
02 ·
Stimuli-Responsive Smart Drugs
We design prodrugs engineered to remain inert in circulation and become active only in the target tissue upon an exogenous or endogenous trigger. This spatial and temporal control over drug activation is a central principle of our drug discovery programme.
03 ·
Inorganic Medicinal Chemistry
Metal-based anticancer therapeutics — platinum, gold, ruthenium, and osmium complexes — form a key pillar of our research. We explore their mechanisms of action, selectively and translational potential in glioblastoma, lung cancer, and other difficult-to-treat tumors.
04 ·
Halogen Bonding & Supramolecular Chemistry
We investigate halogen bonding as a versatile tool for molecular recognition, crystal engineering, and drug design — contributing foundational work on non-covalent interactions in pharmaceutical and materials sciences.
05 ·
Theoretical & Computational Chemistry
DFT calculations and computational modeling underpin our synthetic and mechanistic work — from rationalizing reaction selectivity and conformational properties to understanding drug-target interactions and prodrug activation mechanisms.
06 ·
Neurodegeneration & Inflammaging
Beyond cancer, chronic low-level innate immune activation contributes to Alzheimer's, Parkinson's, and age-related diseases. We develop molecularly targeted approaches to modulate this inflammation — an emerging frontier with no disease-modifying therapies currently available.

Awards & Honours

2023
Maricq Award
Awarded for the best work applying physicochemical methods in drug analysis or toxicological research (Berger et al., Inorg. Chem. 2021)
2021
Andrew Parsa Young Investigator Award
American Society for Neuro-Oncology (SNO) — awarded for groundbreaking work on STING activation in glioblastoma models (PNAS 2022)
2020
Potential Future Leader — EuChemS
Nominated by the European Chemical Society Division of Chemistry in Life Sciences
2016
Young Investigator Award — Pharmaceutical Chemistry
Awarded by the Belgian Committee of Medicinal Chemists
2015
Fulbright Scholar
U.S.-Belgium Fulbright Commission — research fellowship at MIT (Lippard Lab)
2015
BAEF & Hoover Foundation Fellow
Belgian American Educational Foundation fellowship — MIT (Lippard Lab)
2011
UCB-Pharma Award — Medicinal Chemistry Days
Belgium
2010
Best Scientific Communication
PhD Day, Belgium

Grants & Fellowships

2025
FNRS-ASP
160 k€
2025
FNRS-CR (Research Credit)
1,600 k€
2024
FNRS-CDR
62 k€
2023
FNRS-PDR (Research Project)
155 k€
2023
FNRS-FRIA Doctoral Fellowship
150 k€
2023
Télévie Grant
200 k€
2022
FNRS-CDR
60 k€
2018
FRS-FNRS Postdoctoral Fellow
200 k€
2015
Fulbright Scholarship
15 k€
2015
Belgian American Educational Foundation (BAEF)
45 k€
2015
ULB Postdoctoral Fellowship
150 k€

Teaching

Publications

45+
Peer-reviewed articles
4
Journal covers
16+
Invited talks & plenaries
Selected Highlights
STING Activation Promotes Robust Immune Response and NK-Cell Mediated Tumor Regression in Glioblastoma Models
Berger, G. et al.
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G.; Marloye, M.; Lawler, S. E.
Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus
Vernekar, A.; Berger, G.; Czapar, A.; Wang, D. I.; Steinmetz, N.; Lippard, S. J.
Reduction Mechanism of Anticancer Osmium(VI) Complexes Revealed by Atomic Telemetry and Theoretical Calculations
Berger, G.; Wach, A.; Sá, J.; Szlachetko, J.
ORCID ↗ Google Scholar ↗

Invited Talks & Conferences

2023
Translational Aspects in Medicinal Chemistry: From Synthetic and Theoretical Chemistry to Cancer Therapeutics — Invited talk, Brown University, Providence, USA, April 2023
2022
Metal-Based Anticancer Therapeutics: Short Stories — Invited talk, La Sorbonne & ENSCP ParisTech, Paris, March 2022
2021
Short Stories in Medicinal Chemistry — Invited Plenary, MedChem2021, Annual One-Day Meeting SRC & KVCV, Liège, November 2021
2021
STING activation promotes robust immune response and tumor regression in glioblastoma models — 26th Annual Meeting, Society for Neuro-Oncology, Boston, November 2021
2018
Modern Computational Tools in Catalysis, Drug Synthesis and Design — European Workshop in Drug Synthesis, Siena, Italy, May 2018
2017
Explorations of Metal-Based Anticancer Therapeutics — Group Seminar, H. Wennemers Lab, ETH Zürich, November 2017
2017
Explorations of Metal-Based Anticancer Therapeutics — Invited Lecture, University of Tabasco, Mexico, October 2017
2017
Explorations of Metal-Based Anticancer Therapeutics — Award Talk, Journées Franco-Belges de Pharmacochimie, Spa, Belgium, September 2017
2015
Structural Properties of 4,5-Methanoprolines and their Oligomers — European Workshop in Drug Design, Siena, Italy, May 2015
2014
4,5-Methanoprolines, bifunctional-catalyzed aldol reactions and the chemistry of benzodiazidodiazines — Year-End Symposium, Hanessian Group, Université de Montréal, November 2014
2011
Synthesis and In Vitro Anticancer Properties of Platinum Derivatives — 25èmes Journées franco-belges de pharmacochimie, Liège, May 2011
2010
FTIR Spectroscopy to Monitor the Cellular Impact of Newly Synthesized Platinum Derivatives — PhD Day, Mons, May 2010

The people
behind the science

Prof. Gilles Berger
Principal Investigator
Prof. Gilles
Berger

Prof. Berger leads the Laboratory of Medicinal and Translational Chemistry at ULB. His research bridges synthetic organic chemistry, inorganic medicinal chemistry, and translational oncology — with a particular focus on cancer immunotherapy and smart drug design.

His work has produced over 44 publications in leading journals including PNAS, JACS, Angew. Chemie, and Trends in Molecular Medicine, and has been presented at conferences worldwide.

Postdoctoral Researchers
Félix Grosjean
Félix Grosjean
Postdoc
FNRS Postdoctoral Fellow

PhD from the Univ. of Montpellier; postdoc at McGill (Canada). Works on cancer immunotherapy, neurological disorders, and chronic inflammatory diseases.

Doctoral Researchers
Guillaume Blampain
Guillaume Blampain
PhD Student
Teaching Assistant

MSc in Drug Design from the Univ. of Lille. Develops conditionally activated prodrugs targeting innate immune pathways for cancer therapy.

Célia Culot
Célia Culot
PhD Student
FRIA Fellow

MSc in Pharmaceutical Sciences (ULB) and Biotherapeutics (UCD Dublin). Researches novel ruthenium-based prodrugs for immunotherapy applications.

Daan Meurs
Daan Meurs
PhD Student
Télévie Fellow

MSc in Chemistry from KU Leuven (2023). Researches X-ray-activated prodrugs of immunomodulators as adjuvants to radiotherapy.

Xavier Luppens
Xavier Luppens
PhD Student
Aspirant FNRS

MSc in Pharmaceutical Sciences from ULB. Researches novel phosphoantigens for γδ T-cell-based immunotherapy, co-supervised with Prof. Vermijlen (IMI).

Master's Students
Alessandro Spada
Alessandro Spada
MSc Student
Erasmus — Sapienza Roma
Pauline Tronche
Pauline Tronche
MSc Student
Chemical Engineer
LF
Lisa Flasse
MSc Student
MSc Biology

Peer-reviewed
publications

45 articles & 1 book chapter · 4 journal covers · JACS · PNAS · Angew. Chemie · Trends Mol. Med. · and more

(45)
Synthesis, Characterization, and Biological Activity of Cationic Ruthenium–Arene Complexes with Sulfur Ligands
Zain Aldin, M.; Zaragoza, G.; Choquenet, E.; Blampain, G.; Berger, G.; Delaude, L.
(44)
Pseudodiproline (Pro-Cyp) Oligomers Fold into Helical Polyproline Type Secondary Structures
Garsi, J. B.; Aguiar, P. M.; Berger, G.; Maris, T.; Hanessian, S.
(43)
An Anti-Glioblastoma Gold(I)–NHC Complex Distorts Mitochondrial Morphology and Bioenergetics to Induce Tumor Growth Inhibition
Greif, C. E.; Mertens, R. T.; Berger, G.; Awuah, S. G.; Parkin, S.
(42)
Halogen-Bonded Thiophene Derivatives Prepared by Solution and/or Mechanochemical Synthesis. Evidence of N···S Chalcogen Bonds in Homo- and Cocrystals
Kumar, S.; Body, C.; Leyssens, T.; Hecke, K. Van; Berger, G.; Lee, A. Van Der; Laurencin, D.; Richeter, S.; Meyer, F.
(41)
Synthesis and Biological Activity of Iron(II), Iron(III), Nickel(II), Copper(II) and Zinc(II) Complexes of Aliphatic Hydroxamic Acids
Sow, I. S.; Gelbcke, M.; Meyer, F.; Vandeput, M.; Marloye, M.; Basov, S.; Van Bael, M. J.; Berger, G.; Robeyns, K.; Hermans, S.; Yang, D.; Fontaine, V.; Dufrasne, F.
(40)
A Pt(IV)-Conjugated Brain Penetrant Macrocyclic Peptide Shows Pre-Clinical Efficacy in Glioblastoma
Jimenez-Macias, J. L.; Lee, Y.; Miller, E.; Finkelberg, T.; Zdioruk, M.; Berger, G.; Farquhar, C. E.; Nowicki, M. O.; Cho, C.; Fedeles, B. I.; Loas, A.; Pentelute, B. L.
(39)
STING Activation Promotes Robust Immune Response and NK-Cell Mediated Tumor Regression in Glioblastoma Models
Berger, G.; Knelson, E.; Nowicki, M. O.; Jimenez, J. L.; Stafford, A.; Mooney, D. J.; Chiocca, A.; Barbie, D. A.; Lawler, S. E.
(38)
Surprising Chemistry of 6-Azidotetrazolo[5,1-a]Phthalazine: What a Purported Natural Product Reveals about the Polymorphism of Explosives
Arnold, J. E.; Morency, M.; Chartrand, D.; Maris, T.; Berger, G.; Day, G. M.; Hanessian, S.; Wuest, J. D.
(37)
Directed Self-Assembly of Ruthenium and Osmium Nanoparticles Display Potent In Vivo Anticancer Profile by Interfering with Metabolic Activity
Marloye, M.; Mathieu, V.; Debaille, V.; Nowicki, M. O.; Meyer, F.; Lawler, S. E.; Dufrasne, F.; Berger, G.
(36)
Stable Au(I) Catalysts for Oxidant-Free C-H Functionalization with Iodoarenes
Mertens, R. T.; Greif, C. E.; Coogle, J. T.; Berger, G.; Parkin, S.; Watson, M. D.; Awuah, S. G.
(35)
Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease
Schawe, L.; Raude, B.; Carstens, J. C.; Hinterseher, I.; Hein, R. D.; Omran, S.; Berger, G.; Hering, N. A.; Buerger, M.; Greiner, A.; Frese, J. P.
(34)
Catalytic Properties of 4,5-Bridged Proline Methano- and Ethanologues in the Hajos-Parrish Intramolecular Aldol Reaction
Berger, G.*; Hocine, S.*; Houk, K.; Hanessian, S. (*Co-first author)
(33)
Synthesis, Structure and Anticancer Properties of New Biotin‑ and Morpholine‑Functionalized Ruthenium and Osmium Half‑Sandwich Complexes
Marloye, M.; Dufrasne, F.; Meyer, F.; Berger, G.
(32)
Reduction Mechanism of Anticancer Osmium(VI) Complexes Revealed by Atomic Telemetry and Theoretical Calculations
Berger, G.; Wach, A.; Sá, J.; Szlachetko, J.
(31)
Halogen Bonding for Molecular Recognition: New Developments in Materials and Biological Sciences
Berger, G.; Frangville, P.; Meyer, F.
(30)
Design and Synthesis of Backbone-Fused, Conformationally Locked Bridged Morpholine-Proline Chimeras
Hocine, S.; Berger, G.; Hanessian, S.
(29)
Current Patent Status of STING Agonists for Cancer Immunotherapy
Marloye, M.; Lawler, S. E.; Berger, G.
(28)
Methyl Arachidonyl Fluorophosphonate Inhibits Mycobacterium tuberculosis TesA Thioesterase
Yang, D.; Vandenbussche, G.; Vertommen, D.; Wohlkönig, A.; Berger, G.; Khan, M. S.; Zeng, S.; Soumillion, P.; Fontaine, V.
(27)
Direct Intramolecular Carbon(sp²)-Nitrogen(sp²) Reductive Elimination from Gold(III)
Kim, J. H.; Mertens, R. T.; Agarwal, A.; Parkin, S.; Berger, G.; Awuah, S. G.
(26)
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G.; Marloye, M.; Lawler, S. E.
Trends in Molecular Medicine
Front Cover
Vol. 25, Issue 5 · 2019
STING pathway modulation in cancer immunotherapy. Cover design: G. Berger, A. Ignace, S. E. Lawler & M. Vermeersch.
(25)
Novel Non-Nucleotidic STING Agonists for Cancer Immunotherapy (Invited Editorial)
Berger, G.; Lawler, S. E.
(24)
Crystal Packing and Theoretical Analysis of Halogen- and Hydrogen-Bonded Hydrazones from Pharmaceuticals
Berger, G.; Soubhye, J.; Robijns, K.; Meyer, F.
(23)
Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus
Vernekar, A.; Berger, G.; Czapar, A.; Wang, D. I.; Steinmetz, N.; Lippard, S. J.
(22)
Anticancer Activity of Osmium(VI) Nitrido Complexes in Patient-Derived Glioblastoma Initiating Cells and In Vivo Mouse Models
Berger, G.; Grauwet, K.; Zhang, H.; Hussey, A. M.; Nowicki, M. O.; Wang, D. I.; Chiocca, E. A.; Lawler, S. E.; Lippard, S. J.
(21)
Metal Coordination-Controlled and Bifunctional H-Bonded Catalysis in Stereoselective Intramolecular Aldol Cyclizations toward Carbocyclic Tertiary β-Ketols
Chen, B.; Berger, G.; Hanessian, S.
(20)
Triple-Stimuli Responsive Polymers with Fine Tuneable Magnetic Response
Chikh Alard, I.; Soubhye, J.; Berger, G.; Gelbcke, M.; Spassov, S.; Amighi, K.; Goole, J.; Meyer, F.
Polymer Chemistry · RSC
Front Cover
Vol. 8 · 2017
Triple-stimuli responsive polymers with fine tuneable magnetic response.
(19)
Properties of the Amide Bond Involving Proline 4,5-Methanologues: An Experimental and Theoretical Study
Berger, G.; Chab-Majdalani, I.; Hanessian, S.
(18)
A Survey of the Mechanisms of Action of Anticancer Transition Metal Complexes
Marloye, M.; Berger, G.; Gelbcke, M.; Dufrasne, F.
(17)
Development of Controlled-Release Cisplatin Dry Powders for Inhalation Against Lung Cancers
Levet, V.; Rosière, R.; Merlos, R.; Fusaro, L.; Berger, G.; Amighi, K.; Wauthoz, N.
(16)
Novel Bis-Arylalkylamines as Myeloperoxidase Inhibitors: Design, Synthesis, and Structure-Activity Relationship Study
Aldib, I.; Gelbcke, M.; Soubhye, J.; Prévost, M.; Furtmüller, P. G.; Obinger, C.; Elfving, B.; Alard, I. C.; Roos, G.; Delporte, C.; Berger, G.; Dufour, D.; Zouaoui Boudjeltia, K.; Nève, J.; Dufrasne, F.; Van Antwerpen, P.
(15)
Strategies Toward the Total Synthesis of Calyciphylline B-Type Alkaloids: A Computational Perspective Aided by DFT Analysis
Chattopadhyay, A. K.; Berger, G.; Hanessian, S.
(14)
Total Synthesis of Isodaphlongamine H: A Possible Biogenetic Conundrum
Chattopadhyay, A. K.; Ly, V. L.; Jakkepally, S.; Berger, G.; Hanessian, S.
(13)
Resonant X-Ray Emission Spectroscopy of Platinum(II) Anticancer Complexes
Sá, J.; Czapla-Masztafiak, J.; Lipiec, E.; Kayser, Y.; Fernandes, D. L. A.; Szlachetko, J.; Dufrasne, F.; Berger, G.
(12)
Halogen Bonding in a Multi-Connected 1,2,2-Triiodo-Alkene Involving Geminal and/or Vicinal Iodine: A Crystallographic and DFT Study
Berger, G.; Robeyns, K.; Soubhye, J.; Wintjens, R.; Meyer, F.
CrystEngComm · RSC
Cover Article
Vol. 18 · 2016
Halogen bonding in a multi-connected triiodo-alkene: crystallographic and DFT study.
(11)
Structural Properties and Stereochemically Distinct Folding Preferences of 4,5-cis and trans-Methano-l-Proline Oligomers: The Shortest Crystalline PPII-Type Helical Proline-Derived Tetramer
Berger, G.; Vilchis-Reyes, M.; Hanessian, S.
(10)
The Use of Resonant X-Ray Emission Spectroscopy (RXES) for the Electronic Analysis of Metal Complexes and Their Interactions with Biomolecules
Sá, J.; Czapla-Masztafiak, J.; Lipiec, E.; Kayser, Y.; Kwiatek, W.; Wood, B.; Deacon, G. B.; Berger, G.; Dufrasne, F.; Fernandes, D. L. A.; Szlachetko, J.
(9)
Preparation of Racemic and Optically Active Trifluoromethyl Aziridines and Azetidines, in Targets in Heterocyclic Systems
Berger, G.; Wintjens, R.; Meyer, F. In: Attanasi, O. A., Noto, R., Spinelli, D., Eds.
Società Chimica Italiana: Roma, 2014; pp 29–47 [Book chapter]
(8)
Insights into the Structure–Activity Relationships of Chiral 1,2-Diaminophenylalkane Platinum(II) Anticancer Derivatives
Berger, G.; Fusaro, L.; Luhmer, M.; Czapla-Masztafiak, J.; Lipiec, E.; Szlachetko, J.; Kayser, Y.; Fernandes, D. L. A.; Sá, J.; Dufrasne, F.; Bombard, S.
(7)
Halogen Bonding in Polymer Science: From Crystal Engineering to Functional Supramolecular Polymers and Materials
Berger, G.; Soubhye, J.; Meyer, F.
Polymer Chemistry · RSC
Back Cover
Vol. 6, Issue 19 · 2015
Halogen bonding in polymer science: from crystal engineering to functional supramolecular polymers and materials.
(6)
Synthesis of α-CF₃ Azanorbornene and Azetidines by Aza Diels-Alder or Iodine-Mediated Cyclizations: Application in ROMP and Ligand Design
Berger, G.; Fusaro, L.; Luhmer, M.; van der Lee, A.; Crousse, B.; Meyer, F.
(5)
Synthesis and In Vitro Characterization of Platinum(II) Anticancer Coordinates Using FTIR Spectroscopy and NCI COMPARE: A Fast Method for New Compound Discovery
Berger, G.; Leclercq, H.; Derenne, A.; Gelbcke, M.; Goormaghtigh, E.; Nève, J.; Mathieu, V.; Dufrasne, F.
(4)
Interplay Between Halogen Bonding and Lone Pair-π Interactions: A Computational and Crystal Packing Study
Berger, G.; Soubhye, J.; van der Lee, A.; Vande Velde, C.; Wintjens, R.; Dubois, P.; Clément, S.; Meyer, F.
(3)
Using Conceptual DFT to Rationalize Regioselectivity: A Case Study on the Nucleophilic Ring-Opening of Activated Aziridines
Berger, G.
(2)
Synthesis of ¹⁵N-Labeled Vicinal Diamines Through N-Activated Chiral Aziridines: Tools for the NMR Study of Platinum-Based Anticancer Compounds
Berger, G.; Gelbcke, M.; Cauët, E.; Luhmer, M.; Nève, J.; Dufrasne, F.
(1)
Fourier Transform Infrared Spectroscopy to Monitor the Cellular Impact of Newly Synthesized Platinum Derivatives
Berger, G.; Gasper, R.; Lamoral-Theys, D.; Wellner, A.; Gelbcke, M.; Gust, R.; Nève, J.; Kiss, R.; Goormaghtigh, E.; Dufrasne, F.

Lab Equipment
& Facilities

Synthetic Chemistry Cell Biology Computational Core Facilities

Chemical Synthesis Infrastructure

Our synthetic chemistry laboratory is fully equipped for both standard and advanced organic and inorganic synthesis, including air-free and anhydrous conditions essential for sensitive organometallic and medicinal chemistry work.

Schlenk Lines
Air-Free Chemistry
Schlenk Lines & High-Vacuum Pumps
Dual manifold Schlenk lines connected to high-vacuum pumps enable rigorous exclusion of air and moisture — essential for the synthesis of sensitive organometallic complexes and reactive intermediates.
Biotage Flash
Purification
Biotage Flash Chromatography
Automated flash purification system for rapid isolation of synthetic compounds. Compatible with normal and reversed-phase cartridges, enabling efficient purification from milligram to gram scale.
EasyMax Reactor
Automated Synthesis
Mettler-Toledo EasyMax Reactor
Automated synthesis workstation with precise temperature control and real-time monitoring of reaction parameters. Ideal for reaction optimization and reproducible scale-up of key synthetic steps.
Ultrasound Irradiator
Stimuli-Responsive Chemistry
Ultrasound Irradiator
Probe sonicator for sonochemistry and mechanochemical reactions. Used in the synthesis and characterisation of novel drug candidates within our prodrug programme.
Shimadzu LC
Chromatography
Shimadzu Semi-Prep HPLC + Agilent HPLC
Shimadzu semi-preparative LC system with fraction collector for isolation of complex mixtures and final drug candidates, complemented by an Agilent analytical HPLC for purity assessment and method development.
Evaporation
Rotary Evaporators (×2)
Two rotary evaporators for solvent removal under reduced pressure — standard workhorses of synthetic chemistry, enabling efficient workup and concentration of reaction mixtures and chromatography fractions.

Biology Infrastructure

A fully equipped cell and molecular biology suite enables the LMTC to evaluate synthesized compounds in relevant biological models — from cellular assays to immunological readouts.

Cell Culture Room
Tissue Culture
Dedicated Cell Culture Room
Fully equipped BSL-2 tissue and cell culture room with laminar flow hoods and CO₂ incubators. Used for culturing cancer cell lines, primary cells, and patient-derived tumor models.
Molecular Biology Suite
Full complement of molecular biology equipment including PCR thermocyclers (qPCR and end-point), gel electrophoresis, Western blot systems, and ELISA readers for gene expression and protein quantification.
Gallios Flow Cytometer
Immunophenotyping
Beckman Coulter Gallios Flow Cytometer
10-color flow cytometer for high-throughput immunophenotyping, apoptosis assays, cell cycle analysis, and characterization of immune infiltrates in tumor models.
Zeiss Axio Microscope
Fluorescence Microscopy
Zeiss Axio AX10 Microscope
Upright fluorescence microscope for immunofluorescence imaging of cell lines and tumor sections — visualization of immune infiltrates, subcellular localization, and assessment of cell death markers.
Agilent 96-Well Plate Reader
Multi-mode plate reader with bioluminescence and UV-Vis detection. Used for cytotoxicity assays (MTT, resazurin), luciferase-based IRF3 reporter assays for STING pathway activation, and absorbance-based compound quantification.

HPC Computing Clusters

Theoretical and computational chemistry is a cornerstone of the LMTC. Through the CÉCI consortium (Consortium des Équipements de Calcul Intensif), we access five high-performance computing clusters across Belgian universities, totalling thousands of CPU and GPU cores for quantum chemical calculations, molecular dynamics, and large-scale cheminformatics.

Lyra cluster
Lyra
ULB · 1280 cores + 40× NVidia RTX 6000 GPU
Hyperconverged HPC infrastructure optimized for ML/AI and GPU-accelerated computing. Our home cluster at ULB.
Hercules2 cluster
Hercules 2
UNamur · 1024 cores + GPUs
Shared-memory and resource-intensive sequential jobs. Large RAM fat nodes (up to 2 TB) ideal for memory-demanding QM calculations.
Lemaître4 cluster
Lemaître 4
UCLouvain · 5120 cores · 320 TB
High-throughput MPI parallel jobs on AMD EPYC Genoa CPUs. Excellent for large-scale ORCA/Gaussian DFT runs.
NIC5 cluster
NIC 5
ULiège · 4672 cores · 520 TB
Massively parallel MPI cluster on HDR Infiniband. Fat nodes up to 1 TB RAM available for demanding correlated methods (MP2, DLPNO).
Dragon2 cluster
Dragon 2
UMons · 592 cores + V100 GPUs
Long-running jobs (up to 21 days) with NVidia Tesla V100 GPUs. Ideal for extended molecular dynamics simulations and neural network potentials.

Core Facilities

Beyond our in-house infrastructure, we regularly access world-class core facilities at ULB and partner institutions for specialized analyses.

CIREM NMR
ULB · NMR Spectroscopy
CIREM — Centre d'Instrumentation en REsonance Magnétique
The LMTC is a heavy user of ULB's NMR core facility, which houses four high-field spectrometers — two JEOL JNM-ECZ systems (400 and 600 MHz) at the Plaine campus, and Bruker and Varian instruments (300 and 400 MHz) at Solbosch. Prof. Berger sits on the CIREM directing committee, reflecting our deep engagement with this facility. Routine ¹H, ¹³C, DEPT, COSY, HSQC, HMBC, NOESY and variable-temperature experiments are performed here for full structural characterization of novel molecules, including complex multinuclear experiments on our metal complexes.
BRIGHTcore sequencer
VUB / ULB · Genomics
BRIGHTcore — Genomics Core Facility
We access the BRIGHTcore sequencing facility (VUB/ULB) for transcriptomic and genomic analyses — including RNA-seq for immune gene expression profiling, whole genome sequencing, single-cell sequencing, and NGS-based validation in the context of our cancer immunotherapy studies. BRIGHTcore operates a comprehensive instrument fleet including MGI DNBSEQ-T7, Illumina NovaSeq 6000, MiSeq, and NanoPore long-read sequencers, providing high-quality, rapid-turnaround sequencing that complements our in-house molecular biology capabilities.
ULB · Mass Spectrometry
G-Time Laboratory — Quadrupole ICP-MS
Agilent 7700 ICP-MS
We access G-Time's Agilent 7700 quadrupole ICP-MS for elemental and trace metal analysis — directly relevant for characterization of our metal-based anticancer complexes (platinum, gold, ruthenium, osmium) and quantification of metal uptake in biological samples. G-Time operates class-100 and class-1000 clean laboratories and offers dissolution by acid digestion or alkaline fusion, enabling precise multi-element quantification down to trace concentrations.

International
Collaborations

The LMTC maintains active research collaborations with world-leading groups at the interface of chemistry, biology, and medicine — from cancer immunotherapy and brain tumors to inorganic medicinal chemistry and chemical biology.

Cancer Immunotherapy & Oncology
Dana-Farber / Harvard · USA
Active
Dana-Farber Cancer Institute & Harvard Medical School
Cancer immunotherapy and innate immunity; STING pathway activation; tumor microenvironment modeling. Key joint work on STING agonism in glioblastoma (PNAS 2022).
Brown University · USA
Active
Brain Cancer Therapy Lab, Legorreta Cancer Center
Brain cancer biology and glioblastoma; innate immune mechanisms for brain tumor immunotherapy; drug delivery across the blood-brain barrier.
Harvard / Wyss Institute · USA
Active
Harvard SEAS & Wyss Institute for Biologically Inspired Engineering
Smart biomaterials, cancer immunotherapy, immunoengineering; biomaterial-based cancer vaccines; drug delivery scaffolds for localized immunostimulation.
ULB · Belgium
Active
ULB Center for Research in Immunology (U-CRI)
Immunology; γδ T cell biology, development and cancer immunosurveillance; innate lymphocyte responses in infection and tumor contexts.
Jules Bordet / ULB · Belgium
Active
Radiobiology Research Unit, Institut Jules Bordet
Radiotherapy for cancer; radio-immunotherapy combinations; radiobiology, DNA damage response; abscopal effects and FLASH radiotherapy.
Neurosurgery & Brain Cancer Therapy
Harvard Medical School · USA
Active
Harvey W. Cushing Prof. of Neurosurgery, Brigham & Women's / Harvard
Brain cancer gene and viral therapies; oncolytic viruses for glioma; immunotherapeutic approaches for GBM; non-coding RNA in tumor biology.
Chemical Biology & Medicinal Chemistry
Chimie ParisTech · France
Active
Gasser Group — Inorganic Chemical Biology, PSL University / CNRS
Organometallic and medicinal inorganic chemistry; metal complexes as anticancer agents; photodynamic therapy; PNA bioconjugates and halogen bonding.
University of Kentucky · USA
Active
Awuah Research Laboratory, Department of Chemistry
Organometallic and medicinal inorganic chemistry; gold complexes as anticancer agents; chemical immunology; computer-aided drug design and CRISPR-based tools.
MIT · USA
Active
Pentelute Lab, MIT Department of Chemistry
Peptide and protein chemistry; automated fast-flow peptide synthesis; protein bioconjugation; intracellular delivery via anthrax toxin platform; peptidomimetic drug discovery.
Ruhr-Universität Bochum · Germany
Active
Faculty of Chemistry and Biochemistry, RUB
Metal-based photosensitisers and metal-complex prodrugs for chemo-immunotherapy; conditionally activated anticancer agents. Active bilateral DFG/FNRS Weave grant on metal-based STING prodrug systems for cancer immunotherapy.
Université de Montréal · Canada
Active
Hanessian Group, Département de chimie, UdeM
Organic, bioorganic and medicinal chemistry; total synthesis of natural products; Chiron approach to asymmetric synthesis; antibiotic and antiviral drug design.
Inorganic, Medicinal & Supramolecular Chemistry
ULB · Belgium
Active
Laboratoire de Chimie Bioinorganique et Supramoléculaire, ULB
Medicinal inorganic chemistry; metal-based anticancer complexes (Ru, Os, Fe, Cu, Ni); coordination chemistry and supramolecular recognition. Long-standing collaboration on synthesis and evaluation of anticancer metallodrugs.
Uppsala University · Sweden
Department of Chemistry — Ångström Laboratory
X-ray spectroscopy and synchrotron-based methods; electronic structure of metal complexes; resonant X-ray emission spectroscopy (RXES) for mechanistic elucidation of Pt and Os anticancer agents.
ULB · Belgium
Laboratoire de Chimie Organique, ULB
Supramolecular chemistry; anion transport across lipid bilayers; synthetic ion carriers and channels; halogen bonding in recognition and transport. Collaboration on functional supramolecular systems.
ULB · Belgium
Laboratoire de Chimie Organique, ULB
Supramolecular chemistry; calix[6]arene-based receptors and metallocages; molecular encapsulation and host-guest chemistry; anion recognition. Collaboration on self-assembled metallocages for drug delivery.
FRS-FNRS Grant Legend
PDR — Projet de Recherche (2023) EQP — Equipement (2024) TLV — Télévie (2026) Active — active collaboration on the funded topic

News & Updates

Publications, grants, team milestones, awards and talks from the LMTC — from its founding in 2020 to the present.

Publication Grant Award Team Talk News
Apr 2026
Talk
Invited lecture in Ho Chi Minh City, Vietnam
Gilles presents an invited talk — Translational Medicinal Chemistry: From Molecular Orbitals to Tumor Regression — at a scientific meeting in Ho Chi Minh City, Vietnam, covering the lab's journey from computational drug design to in vivo immunotherapy results.
Oct 2025
Team
Xavier Luppens joins as Aspirant FNRS
Xavier Luppens joins the LMTC as a PhD student supported by an FNRS Aspirant fellowship. His doctoral project explores synthetic phosphoantigens for Vγ9Vδ2 T-cell-based cancer immunotherapy, co-supervised with Prof. David Vermijlen (U-CRI, ULB).
2025
Grant
FNRS-ASP fellowship awarded — Xavier Luppens
The FRS-FNRS awards an Aspirant (ASP) PhD fellowship (160 k€) to support Xavier Luppens's doctoral research on γδ T-cell immunotherapy within the LMTC.
2025
Grant
FNRS Chargé de Recherche fellowship awarded — Félix Grosjean
The FRS-FNRS awards a Chargé de Recherche (CR) postdoctoral fellowship (160 k€) to Dr. Félix Grosjean, recognising the quality of his independent research programme at the LMTC.
2024
Publication
New paper on cationic Ru–arene complexes with sulfur ligands
The LMTC contributes to a study on the synthesis, characterisation, and biological activity of cationic ruthenium–arene complexes bearing sulfur donor ligands, published in J. Biol. Inorg. Chem. Guillaume Blampain is among the co-authors.
Apr 2024
Team
Félix Grosjean joins as FNRS Postdoctoral Fellow
Dr. Félix Grosjean joins the LMTC as an FNRS Postdoctoral Fellow. Félix holds a PhD from the University of Montpellier and completed a postdoctoral stay at McGill University. His research focuses on the intersection of cancer immunology, neuroinflammation, and medicinal chemistry.
2024
Grant
FNRS-CDR research credit awarded
The LMTC is awarded an FNRS Crédit de Recherche (CDR, 62 k€) to support ongoing experimental work within the laboratory's active research programmes.
2023
Publication
Two new papers: gold complexes in glioblastoma and proline oligomer folding
The lab contributes to two 2023 publications: a study in RSC Chem. Biol. on an anti-glioblastoma Au(I)–NHC complex that disrupts mitochondrial bioenergetics (with the Awuah Lab, University of Kentucky), and a paper in J. Org. Chem. on pseudodiproline oligomers forming helical PPII-type structures (with the Hanessian Group, Université de Montréal).
2023
Publication
Crystal engineering and coordination chemistry contributions
Two further 2023 publications from the LMTC's collaborative network: a study in Cryst. Growth Des. on halogen-bonded thiophene derivatives with N···S chalcogen bonds (with the Meyer group, ULB), and a paper in J. Coord. Chem. on hydroxamic acid metal complexes.
Oct 2023
Team
Célia Culot and Daan Meurs join the LMTC
The lab welcomes two new PhD students. Célia Culot (FNRS-FRIA Fellow) holds an MSc in Pharmaceutical Sciences from ULB and a biotherapeutics degree from UCD Dublin; she works on Ru-based prodrug systems. Daan Meurs (Télévie Fellow) holds an MSc from KU Leuven and focuses on novel anticancer agents and preclinical evaluation.
2023
Grant
Three new fellowships: FNRS-PDR, FRIA, and Télévie
A strong year for LMTC funding. The lab secures three competitive grants: an FNRS Projet de Recherche (PDR, 155 k€); an FNRS-FRIA doctoral fellowship (150 k€) for Célia Culot; and a Télévie cancer research fellowship (200 k€) for Daan Meurs — totalling 505 k€ awarded in a single year.
Apr 2023
Talk
Invited talk at Brown University
Gilles delivers an invited lecture — Translational Aspects in Medicinal Chemistry: From Synthetic and Theoretical Chemistry to Cancer Therapeutics — at Brown University, Providence (USA), at the invitation of collaborator Prof. Sean Lawler.
Feb 2023
Team
Guillaume Blampain joins as Teaching Assistant
Guillaume Blampain joins the LMTC as a Teaching Assistant and PhD student. Guillaume holds an MSc from the University of Lille. His doctoral work focuses on conditionally activated prodrugs targeting innate immune pathways.
Feb 2023
Award
Maricq Award
Gilles receives the Maricq Award, recognising his contributions to inorganic chemistry and in particular the mechanistic study of osmium(VI) anticancer complexes published in Inorganic Chemistry (2021, with Jacinto Sá, Uppsala).
2022
Publication
Six publications in 2022, led by the landmark PNAS paper
The LMTC's most prolific year to date: the PNAS 2022 paper demonstrating STING-driven NK-cell tumour regression in glioblastoma models (Andrew Parsa Award); a study on brain-penetrant Pt(IV)-macrocyclic peptide conjugates (J. Control. Release); the Ru/Os nanoparticle paper (Inorg. Chem. Front.); an organocatalysis contribution (Org. Chem. Front.); and further papers in J. Org. Chem., J. Catal. and Biomolecules.
2022
Grant
FNRS-CDR research credit awarded
The LMTC receives its first FNRS Crédit de Recherche (CDR, 60 k€), supporting targeted experimental work and building the lab's early research infrastructure.
Mar 2022
Talk
Invited talks at La Sorbonne and ENSCP ParisTech
Gilles presents Metal-Based Anticancer Therapeutics: Short Stories as an invited speaker at La Sorbonne and the École Nationale Supérieure de Chimie ParisTech, Paris.
Nov 2021
Award
Andrew Parsa Young Investigator Award — Society for Neuro-Oncology
Gilles receives the Andrew Parsa Young Investigator Award at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) in Boston, USA — recognising outstanding contributions by a junior investigator in neuro-oncology.
Nov 2021
Talk
Invited plenary at MedChem2021 and SNO presentation
Gilles delivers an invited plenary — Short Stories in Medicinal Chemistry — at the Annual Medicinal Chemistry Meeting of the SRC & KVCV in Liège; and presents the STING/glioblastoma programme at the SNO Annual Meeting in Boston.
Sep 2021
News
Visiting Scholar at the Wyss Institute, Harvard University
Gilles spends time as Visiting Scholar in the Mooney Lab at the Wyss Institute for Biologically Inspired Engineering at Harvard, working on biomaterial-based intracranial immunotherapies for brain tumours.
2021
Publication
Two papers in 2021: osmium complexes and Ru/Os half-sandwich anticancer agents
The LMTC publishes two papers: a mechanistic study of anticancer osmium(VI) complexes in Inorganic Chemistry (synchrotron-based atomic telemetry, with Jacinto Sá, Uppsala University), and a paper on biotin- and morpholine-functionalized Ru/Os half-sandwich complexes in J. Biol. Inorg. Chem.
2020
Publication
Two publications: halogen bonding review and proline chimera synthesis
The lab's first LMTC-affiliated publications: a Chemical Communications invited review on halogen bonding for molecular recognition (with Franck Meyer, ULB), and a paper in J. Org. Chem. on backbone-fused morpholine-proline chimeras (with the Hanessian Group, Université de Montréal).
2020
News
Nominated as Potential Future Leader by EuChemS
Gilles is nominated as Potential Future Leader by the European Chemical Society (EuChemS) Division of Chemistry in Life Sciences — a recognition of emerging scientists shaping the future of chemistry in Europe.
2020
News
LMTC founded — Gilles Berger appointed Associate Professor at ULB
The Laboratory of Medicinal and Translational Chemistry (LMTC) is established at the Faculty of Pharmacy, Université Libre de Bruxelles (ULB), Campus Erasme. Gilles Berger joins as Associate Professor and Principal Investigator, bringing expertise in medicinal chemistry, cancer immunotherapy, and translational biology.

News & Updates

Publications, grants, awards, new team members, and talks from the LMTC — from September 2021 onwards.

Apr 2026
Talk
Invited Talk — Ho Chi Minh City, Vietnam
Prof. Berger presents Translational Medicinal Chemistry: From Molecular Orbitals to Tumor Regression at the Faculty of Pharmacy, University of Medicine and Pharmacy of Ho Chi Minh City (UMP-HCMC). The talk covers the full arc of the LMTC's research — from computational drug design and chemical synthesis through to in vivo models of cancer immunotherapy.
Oct 2025
People
Xavier Luppens joins the LMTC
Xavier Luppens joins the laboratory as Aspirant FNRS, funded by a competitive four-year PhD fellowship from the FRS-FNRS. His doctoral project focuses on synthetic phosphoantigens engaging the butyrophilin–Vγ9Vδ2 T cell axis for cancer immunotherapy, co-supervised with Prof. David Vermijlen (U-CRI, ULB).
2025
Funding
Two FNRS Fellowships Awarded
The LMTC receives two new competitive fellowships from the FRS-FNRS. The Chargé de Recherche (CR) fellowship supports Dr. Félix Grosjean's independent postdoctoral research project (160 k€). The Aspirant fellowship supports Xavier Luppens's doctoral work (160 k€).
Apr 2024
People
Félix Grosjean joins as FNRS Postdoctoral Fellow
Dr. Félix Grosjean joins the LMTC as Postdoctoral Fellow, funded by a prestigious FNRS Chargé de Recherche fellowship. Félix completed his PhD between Montpellier and McGill before joining the lab, where his research spans cancer immunology and neuroinflammation.
2024
Funding
FNRS Crédit de Recherche — 62 k€
The laboratory is awarded a new FNRS Crédit de Recherche (CDR, 62 k€), supporting targeted experimental work within an ongoing research programme in anticancer drug design.
2024
Publication
Cationic Ruthenium–Arene Complexes with Sulfur Ligands
Zain Aldin, M.; Zaragoza, G.; Choquenet, E.; Blampain, G.; Berger, G.; Delaude, L. publish a study on the synthesis, characterisation, and biological activity of cationic Ru–arene complexes bearing sulfur ligands. J. Biol. Inorg. Chem. 2024, 29 (4), 441–454.
Read more ↗
Oct 2023
People
Célia Culot and Daan Meurs join the LMTC
Two new doctoral researchers join the laboratory simultaneously. Célia Culot (FRIA Fellow, FRS-FNRS) will develop ruthenium-based prodrug systems for cancer therapy. Daan Meurs (Télévie Fellow) will investigate novel anticancer agents and their preclinical evaluation. Both hold MSc degrees in Pharmaceutical Sciences.
2023
Funding
Three Competitive Grants — 505 k€ Total
A strong funding year for the LMTC: the FRS-FNRS awards a Projet de Recherche (PDR, 155 k€) and a FRIA doctoral fellowship for Célia Culot (150 k€); Télévie awards a cancer research fellowship for Daan Meurs (200 k€). Combined with existing grants, the lab now supports five researchers.
Apr 2023
Talk
Invited Talk — Brown University, Providence, USA
Prof. Berger delivers an invited lecture at Brown University (Legorreta Cancer Center) on Translational Aspects in Medicinal Chemistry: From Synthetic and Theoretical Chemistry to Cancer Therapeutics, covering the LMTC's work on STING immunotherapy, metal-based anticancer agents, and smart drug design.
2023
Publication
Anti-Glioblastoma Gold(I)–NHC Complex (RSC Chem. Biol.)
Greif, C. E.; Mertens, R. T.; Berger, G.; Awuah, S. G.; Parkin, S. An anti-glioblastoma Gold(I)–NHC complex that distorts mitochondrial morphology and bioenergetics. RSC Chem. Biol. 2023, 4, 592–599.
Read more ↗
2023
Publication
Pseudodiproline Oligomers — Helical Polyproline Structures (J. Org. Chem.)
Garsi, J. B.; Aguiar, P. M.; Berger, G.; Maris, T.; Hanessian, S. Pseudodiproline (Pro-Cyp) oligomers fold into helical polyproline type secondary structures. J. Org. Chem. 2023, 89, 4283–4293.
Read more ↗
Feb 2023
People
Guillaume Blampain joins the LMTC
Guillaume Blampain joins as Teaching Assistant, combining research and teaching duties. His MSc in Pharmaceutical Sciences from the University of Lille feeds into a project on conditionally activated prodrugs designed to reactivate innate immune signalling in the tumour microenvironment.
Jul 2022
Publication
PNAS — STING Activation and NK-Cell Mediated Tumor Regression in Glioblastoma
Berger, G.; Knelson, E.; Nowicki, M. O.; et al.; Lawler, S. E. demonstrate that STING pathway activation elicits robust anti-tumour immune responses — including NK cell-mediated regression — in glioblastoma models. A landmark paper from the LMTC's Harvard-era work, now published as a first-author PNAS paper. This study establishes the STING axis as a tractable immunotherapy target in brain cancer.
Read more ↗
Mar 2022
Talk
Invited Talk — La Sorbonne & ENSCP ParisTech, Paris
Prof. Berger presents Metal-Based Anticancer Therapeutics: Short Stories at La Sorbonne and the École Nationale Supérieure de Chimie ParisTech, covering the lab's work on platinum, gold, ruthenium, and osmium complexes as anticancer agents.
Feb 2022
Award
Maricq Award
Prof. Berger receives the Maricq Award, recognising outstanding contributions in inorganic and physical chemistry. The award is linked to the publication on the reduction mechanism of anticancer osmium(VI) complexes elucidated by atomic telemetry and theoretical calculations (Inorg. Chem. 2021).
2022
Funding
FNRS Crédit de Recherche — 60 k€
The LMTC is awarded an FNRS Crédit de Recherche (CDR, 60 k€) to support experimental activities in the laboratory's anticancer drug discovery programme.
2022
Publication
Pt(IV) Macrocyclic Peptide Conjugate for Glioblastoma (J. Control. Release)
Jimenez-Macias, J. L.; …; Berger, G.; …; Pentelute, B. L. A brain-penetrant Pt(IV)-conjugated macrocyclic peptide showing preclinical efficacy in glioblastoma. J. Control. Release 2022, 352, 623–636.
Read more ↗
2022
Publication
Ruthenium and Osmium Nanoparticles — In Vivo Anticancer Profile (Inorg. Chem. Front.)
Marloye, M.; …; Berger, G. Directed self-assembly of Ru and Os nanoparticles displaying potent in vivo anticancer activity by interfering with metabolic activity. Inorg. Chem. Front. 2022, 9, 2594–2607.
Read more ↗
2022
Publication
Hajos-Parrish Aldol Reaction — Bridged Proline Analogues (Org. Chem. Front.)
Berger, G.*; Hocine, S.*; Houk, K.; Hanessian, S. Catalytic properties of 4,5-bridged proline methano- and ethanologues in the Hajos-Parrish intramolecular aldol reaction. Org. Chem. Front. 2022, 9, 649–659.
Read more ↗
Nov 2021
Award
Andrew Parsa Young Investigator Award — Society for Neuro-Oncology
Prof. Berger receives the Andrew Parsa Young Investigator Award at the 26th Annual Meeting of the Society for Neuro-Oncology (Boston), recognising his work on STING pathway activation in glioblastoma. He presents the findings that would later appear in PNAS 2022.
Nov 2021
Talk
Invited Plenary — MedChem2021, Liège
Prof. Berger delivers an invited plenary lecture at MedChem2021 (Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCV, Liège) on Short Stories in Medicinal Chemistry, drawing on the LMTC's work across metal-based drugs, STING immunotherapy, and organocatalysis.
Sep 2021
People
LMTC is launched at ULB
The Laboratory of Medicinal and Translational Chemistry officially opens at the Faculty of Pharmacy, Campus Erasme, Université Libre de Bruxelles. Prof. Gilles Berger takes up his position as Associate Professor and Principal Investigator, bringing expertise from postdoctoral training at MIT, Harvard Medical School, and the Wyss Institute.
2021
Publication
Osmium(VI) Reduction Mechanism by Atomic Telemetry (Inorg. Chem.)
Berger, G.; Wach, A.; Sá, J.; Szlachetko, J. The reduction mechanism of anticancer osmium(VI) complexes revealed by synchrotron-based atomic telemetry and theoretical calculations. Inorg. Chem. 2021, 60, 6663–6671.
Read more ↗
2021
Publication
Biotin- and Morpholine-Functionalized Ru/Os Half-Sandwich Complexes (J. Biol. Inorg. Chem.)
Marloye, M.; Dufrasne, F.; Meyer, F.; Berger, G. Synthesis, structure, and anticancer properties of new biotin- and morpholine-functionalised ruthenium and osmium half-sandwich complexes. J. Biol. Inorg. Chem. 2021, 26, 535–549.
Read more ↗
2020
Publication
Halogen Bonding for Molecular Recognition (Chem. Commun.)
Berger, G.; Frangville, P.; Meyer, F. A feature article reviewing new developments in halogen bonding for molecular recognition, covering materials science and biological applications. Chem. Commun. 2020, 56, 4970–4981.
Read more ↗
2020
Publication
Backbone-Fused Morpholine-Proline Chimeras (J. Org. Chem.)
Hocine, S.; Berger, G.; Hanessian, S. Design and synthesis of backbone-fused, conformationally locked bridged morpholine-proline chimeras. J. Org. Chem. 2020, 85, 6, 4237–4247.
Read more ↗

Grants & Fellowships

The LMTC is supported by a sustained portfolio of competitive funding from Belgian, European, and international agencies.

Current Grants
FRS-FNRS · Belgium
Télévie · 2023
Télévie Fellow — Daan Meurs
Active 200 k€
Télévie is the cancer research fundraising campaign of the FRS-FNRS, awarding competitive fellowships for PhD and postdoctoral projects directly targeting cancer. This fellowship supports Daan Meurs, Télévie Fellow at the LMTC, for his doctoral research on novel anticancer agents and their evaluation in preclinical models.
Télévie ↗
FRS-FNRS · Belgium
CR · 2025
Chargé de Recherche — Félix Grosjean
Active 160 k€
FNRS Chargé de Recherche (CR) is a prestigious personal postdoctoral fellowship awarded to outstanding researchers. This fellowship supports Dr. Félix Grosjean, Postdoctoral Fellow at the LMTC, for his independent research project at the interface of cancer immunology and medicinal chemistry.
FRS-FNRS ↗
FRS-FNRS · Belgium
ASP · 2025
Aspirant FNRS
Active 160 k€
FNRS Aspirant is a four-year PhD fellowship for high-potential doctoral candidates. This fellowship supports Xavier Luppens, Aspirant FNRS at the LMTC, for his doctoral research on phosphoantigens and γδ T-cell-based cancer immunotherapy, co-supervised with Prof. David Vermijlen.
FRS-FNRS ↗
FRS-FNRS · Belgium
CDR · 2024
Crédit de Recherche
Active 62 k€
Smaller-scale FNRS research credit supporting targeted experimental work and consumables within an ongoing research theme of the LMTC.
FRS-FNRS ↗
FRS-FNRS · Belgium
PDR · 2023
Projet de Recherche
Active 155 k€
FNRS project grant supporting a defined research axis within the LMTC, funding personnel and experimental costs for a targeted multi-year scientific project.
FRS-FNRS ↗
FRS-FNRS · Belgium
FRIA · 2023
Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture
Active 150 k€
FNRS-FRIA is a four-year PhD fellowship for doctoral candidates with an engineering or applied science background. This fellowship supports Célia Culot, FRIA Fellow at the LMTC, for her doctoral research on ruthenium-based prodrug systems for cancer therapy.
FRS-FNRS ↗
DFG / FRS-FNRS · Germany–Belgium
Weave · 2024–2025
DFG/FNRS Bilateral Weave Grant
In preparation
Bilateral research grant co-funded by the Deutsche Forschungsgemeinschaft (DFG) and the FRS-FNRS, supporting collaborative work between the LMTC (ULB) and a partner laboratory at Ruhr-Universität Bochum. The Weave instrument is designed to foster international research partnerships between national funding agencies.
DFG ↗
Past Grants
FRS-FNRS · Belgium
CDR · 2022
Crédit de Recherche
Completed 60 k€
FNRS research credit funding targeted experimental work and consumables within the LMTC's anticancer drug discovery programme.
FRS-FNRS ↗
FRS-FNRS · Belgium
FNRS Fellowship · 2018
Postdoctoral Research Fellowship
Completed 200 k€
Prestigious FNRS Postdoctoral Fellowship awarded to Prof. Berger for independent research at Harvard Medical School and Brigham and Women's Hospital (Boston, USA). This fellowship enabled foundational work on STING pathway activation in glioblastoma, leading to the landmark PNAS 2022 publication.
FRS-FNRS ↗
Fellowships & Personal Awards
Fulbright Commission · Belgium–USA
Fulbright Scholar · 2015
Fulbright Scholar Award
Completed 15 k€
The Fulbright Scholar Award is one of the most prestigious international academic fellowships, granted by the US Department of State. Prof. Berger received this award to support a postdoctoral fellowship at the Massachusetts Institute of Technology (MIT), working in the Lippard Laboratory on anticancer metallodrugs.
Fulbright Belgium ↗
BAEF / Hoover Foundation · Belgium–USA
BAEF & Hoover Fellow · 2015
Belgian American Educational Foundation Fellowship
Completed 45 k€
The Belgian American Educational Foundation (BAEF) promotes academic and scientific exchanges between Belgium and the United States. Together with the Hoover Foundation, this fellowship supported Prof. Berger's postdoctoral stay at MIT. The BAEF is one of the oldest Belgian-American scientific exchange programmes, founded in 1920.
BAEF ↗
Université Libre de Bruxelles · Belgium
ULB Postdoctoral Fellowship · 2015
ULB Postdoctoral Research Award
Completed 150 k€
Institutional postdoctoral fellowship awarded by ULB to support a research stay abroad at MIT. This grant complemented the Fulbright and BAEF awards and underpinned Prof. Berger's early independent research trajectory in medicinal inorganic chemistry.
ULB Research ↗
About Our Funding Agencies
FRS-FNRS — Fonds de la Recherche Scientifique. The main public research funding body in French-speaking Belgium, supporting fundamental and applied research across all disciplines. frs-fnrs.be ↗
Télévie — Annual cancer research fundraising campaign run by the FRS-FNRS and RTL Belgium. Funds PhD and postdoctoral projects in cancer biology and drug discovery. televie.be ↗
DFG — Deutsche Forschungsgemeinschaft. The central self-governing research funding organisation in Germany, supporting all areas of science and the humanities. dfg.de ↗
Fulbright — US Department of State flagship international educational exchange programme, operating in over 160 countries. fulbrightbelgium.be ↗
BAEF — Belgian American Educational Foundation. Non-profit promoting Belgian-American scientific exchange since 1920, through competitive fellowships at US universities. baef.be ↗

Lab News

Publications, grants, team milestones, talks, and awards from the LMTC — since 2020.

2026
Apr 2026
Talk / Conference
Invited lecture in Ho Chi Minh City
Prof. Berger delivers an invited conference lecture at the University of Medicine and Pharmacy of Ho Chi Minh City, Vietnam. The talk, titled "Translational Medicinal Chemistry: From Molecular Orbitals to Tumor Regression", presents the LMTC's research trajectory to an international audience and opens discussions on future collaborative opportunities in Southeast Asia.
2025
Oct 2025
Team
Xavier Luppens joins as Aspirant FNRS
Xavier Luppens joins the LMTC as a doctoral researcher, funded by a competitive FNRS Aspirant fellowship. His thesis will develop synthetic phosphoantigens for γδ T-cell-based cancer immunotherapy, co-supervised with Prof. David Vermijlen (ULB).
2025
Grant
FNRS Chargé de Recherche awarded to Félix Grosjean
The FRS-FNRS awards a Chargé de Recherche (CR) personal postdoctoral fellowship to Dr. Félix Grosjean, recognising the excellence of his independent research project at the interface of cancer immunology and medicinal chemistry. FRS-FNRS ↗
2025
Grant
FNRS Aspirant fellowship for Xavier Luppens
The FRS-FNRS awards a four-year Aspirant doctoral fellowship to Xavier Luppens, supporting his thesis on phosphoantigen-based γδ T-cell immunotherapy. FRS-FNRS ↗
2024
Apr 2024
Team
Félix Grosjean joins as FNRS Postdoctoral Fellow
Dr. Félix Grosjean joins the LMTC as Postdoctoral Fellow. He brings expertise spanning oncology and neuroinflammation, with a PhD from Montpellier and training at McGill University. His work at the LMTC bridges immunopharmacology and chemical biology.
2024
Grant
FNRS Crédit de Recherche (CDR) awarded
The FRS-FNRS awards a Crédit de Recherche to the LMTC, providing targeted funding for ongoing experimental work within the laboratory. FRS-FNRS ↗
2024
Publication
New paper on Ru–arene complexes in J. Biol. Inorg. Chem.
Zain Aldin, M.; Zaragoza, G.; Choquenet, E.; Blampain, G.; Berger, G.; Delaude, L. — Synthesis, characterization and biological activity of cationic ruthenium–arene complexes with sulfur ligands. J. Biol. Inorg. Chem. 2024 ↗
2023
Oct 2023
Team
Célia Culot and Daan Meurs join the LMTC
Célia Culot (FRIA Fellow) joins with a dual background in Pharmaceutical Sciences (ULB) and Biotherapeutics (UCD Dublin), focusing on ruthenium-based prodrug systems. Daan Meurs (Télévie Fellow, MSc KU Leuven) will develop novel anticancer agents and evaluate them in preclinical models. Both begin their doctoral projects in October 2023.
Apr 2023
Talk / Conference
Invited lecture at Brown University
"Translational Aspects in Medicinal Chemistry: From Synthetic and Theoretical Chemistry to Cancer Therapeutics." Invited talk at the Legorreta Cancer Center, Brown University, Providence, USA.
Feb 2023
Team
Guillaume Blampain joins as Teaching Assistant
Guillaume Blampain joins the LMTC as Teaching Assistant. With an MSc in Drug Design from the University of Lille, he contributes to both the medicinal chemistry teaching programme at ULB/UMONS and to LMTC's research on conditionally activated prodrugs for cancer therapy.
2023
Grant
FNRS-PDR, FRIA, and Télévie grants awarded
A strong funding year for the LMTC: the FRS-FNRS awards a Projet de Recherche (PDR, 155 k€) for a defined research axis; a FRIA doctoral fellowship supporting Célia Culot (150 k€); and a Télévie cancer research fellowship for Daan Meurs (200 k€). Total: 505 k€ in new competitive funding. FRS-FNRS ↗
2023
Publication
Four new papers across RSC, ACS, and Taylor & Francis
Greif, C. E. et al.; Berger, G. — Gold(I)/NHC complex against GBM (RSC Chem. Biol.). Garsi, J. B.; Berger, G.; Hanessian, S. — Pro-Cyp helical oligomers (J. Org. Chem.). Kumar, S. et al.; Berger, G.; Meyer, F. — Halogen-bonded thiophene cocrystals (Cryst. Growth Des.). Sow, I. S. et al.; Berger, G. — Metal complexes of hydroxamic acids (J. Coord. Chem.).
2022
Mar 2022
Talk / Conference
Invited lecture at La Sorbonne and ENSCP ParisTech
"Metal-Based Anticancer Therapeutics: Short Stories." Invited talk at La Sorbonne and the École Nationale Supérieure de Chimie ParisTech, Paris, France.
Feb 2022
Award
Maricq Award
Prof. Berger receives the Maricq Award in recognition of the work on the reduction mechanism of anticancer osmium(VI) complexes (Inorg. Chem. 2021), elucidating drug activation at the atomic level using synchrotron X-ray spectroscopy and DFT calculations. Inorg. Chem. 2021 ↗
2022
Publication
Landmark PNAS paper: STING activation drives NK-cell tumor regression in GBM
Berger, G.; Knelson, E.; Nowicki, M. O. et al.; Lawler, S. E. — STING activation promotes robust immune response and NK-cell mediated tumor regression in glioblastoma models. First-author publication demonstrating for the first time that STING agonism drives NK-cell-dependent tumor regression in preclinical GBM models. PNAS 2022 ↗
2022
Publication
Six additional peer-reviewed articles
Jimenez-Macias, J. L. et al.; Berger, G. — Pt(IV)–macrocyclic peptide for GBM (J. Control. Release). Marloye, M. et al.; Berger, G. — Ru/Os nanoparticles in vivo (Inorg. Chem. Front.). Berger, G.*; Hocine, S.* et al. — Hajos-Parrish aldol with bridged prolines (Org. Chem. Front.). Mertens, R. T. et al.; Berger, G. — Au(I) C-H functionalization (J. Catal.). Arnold, J. E. et al.; Berger, G. — Explosive polymorphism (J. Org. Chem.). Schawe, L. et al.; Berger, G. — VEGF in peripheral arterial disease (Biomolecules).
2022
Grant
FNRS Crédit de Recherche (CDR) awarded
The FRS-FNRS awards a Crédit de Recherche (60 k€) supporting targeted experimental work within the LMTC's anticancer programme. FRS-FNRS ↗
2021
Nov 2021
Award
Andrew Parsa Young Investigator Award — Society for Neuro-Oncology
Prof. Berger receives the Andrew Parsa Young Investigator Award at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO, Boston), recognising outstanding contributions to brain tumor research. The award accompanies an invited oral presentation on STING-mediated tumor regression in GBM.
Nov 2021
Talk / Conference
Invited plenary at MedChem2021 and oral presentation at SNO Boston
Two high-profile presentations in the same month: an invited plenary at the Annual One-Day Meeting on Medicinal Chemistry (SRC & KVCV, Liège, Belgium) and a talk at the 26th Annual SNO Meeting in Boston.
Sep 2021
Appointment
Visiting Scholar at the Wyss Institute for Biologically Inspired Engineering, Harvard
Prof. Berger joins the Wyss Institute at Harvard University as Visiting Scholar, working in the David Mooney laboratory on biomaterial-based intracranial immunotherapies for brain cancers — extending the translational axis of the LMTC's GBM research.
2021
Publication
Two publications: osmium(VI) mechanism and Ru/Os half-sandwich complexes
Berger, G.; Wach, A.; Sá, J.; Szlachetko, J. — Reduction mechanism of anticancer Os(VI) complexes revealed by atomic telemetry and theoretical calculations (Inorg. Chem. 2021, Maricq Award). Marloye, M.; Dufrasne, F.; Meyer, F.; Berger, G. — Biotin- and morpholine-functionalized Ru/Os half-sandwich anticancer complexes (J. Biol. Inorg. Chem. 2021). Inorg. Chem. 2021 ↗
2020
2020
Appointment
Prof. Berger appointed Associate Professor at ULB — LMTC founded
Gilles Berger joins the Université Libre de Bruxelles as Associate Professor and Principal Investigator, founding the Laboratory of Medicinal and Translational Chemistry (LMTC). The laboratory's research spans cancer immunotherapy, precision prodrug design, inorganic medicinal chemistry, and chemical biology.
2020
Award
Nominated as Potential Future Leader — EuChemS Division of Chemistry in Life Sciences
Prof. Berger is nominated as a Potential Future Leader by the European Chemical Society (EuChemS), Division of Chemistry in Life Sciences, in recognition of his emerging contributions to medicinal chemistry and drug discovery.
2020
Publication
Two publications: halogen bonding review and conformationally locked proline chimeras
Berger, G.; Frangville, P.; Meyer, F. — Halogen bonding for molecular recognition: new developments in materials and biological sciences (Chem. Commun. 2020, 56, 4970–4981). Hocine, S.; Berger, G.; Hanessian, S. — Design and synthesis of backbone-fused morpholine-proline chimeras (J. Org. Chem. 2020). Chem. Commun. 2020 ↗